Adaptimmune Therapeutics plc, of Oxford, U.K., said it is expanding its T-cell therapy development activities to target certain autoimmune diseases and named P. Julian Dyson to head that effort. Adaptimmune's goal is to restore the function of the immune system and inhibit the autoimmune response by delivering affinity enhanced regulatory T cells, or Tregs, to the site of the disease.